SNGXW (Soligenix) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)

Soligenix SNGXW 23 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates SNGXW with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

Soligenix's ROE % for the quarter that ended in Mar. 2026 was -269.63%. Soligenix's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Soligenix's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Soligenix ROE % Adjusted to Book Value Related Terms

Soligenix ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Soligenix's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Soligenix ROE % Adjusted to Book Value Chart

Soligenix Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

0.00

Soligenix Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

SNGXW vs BCAB, APM, LABT: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Soligenix's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Soligenix ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Soligenix's ROE % Adjusted to Book Value falls into.

Save Embed

23GF Score

Soligenix Inc SNGXW

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Soligenix ROE % Adjusted to Book Value Calculation

Soligenix's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-235.49%	/	N/A
	=	N/A

Soligenix's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-269.63%	/	N/A
	=	N/A

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 0.00% mean?

Soligenix (SNGXW) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Soligenix and its competitors.

Is Soligenix's ROE % Adjusted to Book Value too high?

Soligenix's current ROE % Adjusted to Book Value is 0.00%. Overall, Soligenix has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.

How does Soligenix's ROE % Adjusted to Book Value compare to BCAB and APM?

Soligenix's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Soligenix and its competitors. Soligenix's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Soligenix stock overvalued right now?

Soligenix (SNGXW) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Soligenix's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For Soligenix (SNGXW), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Soligenix Business Description

Industry Healthcare Biotechnology

Comparable Companies BCAB APM LABT PULM CDIO NCNA NXTC CNSP ENVB APVO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges SNGX:USA 0A6I:UK

Address 29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540

Website https://www.soligenix.com

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

23GF Score

Get the complete analysis for SNGXW

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01

Price

View SNGXW Analysis

See ROE % Adjusted to Book Value data for all stocks →